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Abstract 
Clustered, regularly interspaced, short palindromic repeats (CRISPR) and CRISPR-associated 
proteins (Cas) have recently opened a new avenue for gene therapy. Cas9 nuclease guided by a 
single-guide RNA (sgRNA) has been extensively used for genome editing. Currently, three Cas9 
orthologs have been adapted for in vivo genome engineering applications: SpyCas9, SauCas9 and 
CjeCas9. However, additional in vivo editing platforms are needed, in part to enable a greater 
range of sequences to be accessed via viral vectors, especially those in which Cas9 and sgRNA 
are combined into a single vector genome. Here, we present an additional in vivo editing platform 
using Neisseria meningitidis Cas9 (NmeCas9). NmeCas9 is compact, edits with high accuracy, and 
possesses a distinct PAM, making it an excellent candidate for safe gene therapy applications. We 
find that NmeCas9 can be used to target the Pcsk9 and Hpd genes in mice. Using tail vein 
hydrodynamic-based delivery of NmeCas9 plasmid to target the Hpd gene, we successfully 
reprogrammed the tyrosine degradation pathway in Hereditary Tyrosinemia Type I mice. More 
importantly, we delivered NmeCas9 with its single-guide RNA in a single recombinant adeno-
associated vector (rAAV) to target Pcsk9, resulting in lower cholesterol levels in mice. This all-in-
one vector yielded >35% gene modification after two weeks of vector administration, with 
minimal off-target cleavage in vivo. Our findings indicate that NmeCas9 can facilitate future 
efforts to correct disease-causing mutations by expanding the targeting scope of RNA-guided 
nucleases. 
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Significance 
We and others have shown that NmeCas9 is an efficient Cas9 nuclease with a high degree of 
specificity in cultured human cells. NmeCas9 has a unique PAM that expands the targeting 
range of Cas9-based genome editing. Since NmeCas9 is more compact than SpyCas9, its 
delivery with its guide-RNA in a single recombinant adeno-associated virus becomes a viable 
option. Furthermore, NmeCas9 has an unusually low off-target profile. These characteristics 
make NmeCas9 a strong candidate for in vivo genome editing, including therapeutic gene 
knockouts, as we demonstrate in the mouse liver. We anticipate that successful in vivo delivery of 
this accurate and effective Cas9 can advance therapeutic editing in humans.  
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Introduction  
 
A major advance in the field of gene therapy has been the introduction of Cas9 nuclease-enabled 
genome editing (1). Clustered, regularly interspaced, short palindromic repeats (CRISPR) loci 
specify an adaptive immune pathway that evolved in bacteria and archaea to defend against 
mobile genetic elements (MGEs) (2, 3). The effector complex in type II CRISPR systems includes 
the Cas9 nuclease, which is guided by a CRISPR RNA (crRNA) and a trans-activating RNA 
(tracrRNA). These dual RNAs can be fused to form a single-guide RNA (sgRNA) (4). Each 
crRNA contains a unique “spacer” sequence that can be programmed to cleave a DNA segment 
of interest. Cas9 scans DNA for a specific Protospacer Adjacent Motif (PAM), opens the duplex 
to form an RNA-DNA hybrid between the guide and the spacer, and introduces a double-strand 
break (DSB) in the DNA target (1, 3). Cas9 and sgRNA have been adapted to enable genome 
editing in cultured cells following various modes of delivery including plasmid and RNA 
transfections, viral transduction, and ribonucleoprotein (RNP) electroporation. Precise and 
efficient in vivo editing is more difficult to achieve, largely due to the difficulties inherent in 
delivery.  
Several methods have been developed to deliver Cas9 in vivo including viral and non-viral 
methods (5). These include the use of gold and lipid nanoparticles to deliver Cas9 in RNP or 
RNA form in mice. However, these methods present challenges for routine use including cost 
and tissue distribution (6-8). One of the more intriguing gene delivery vehicles that has emerged 
in recent years is recombinant adeno-associated virus (rAAV). This vector possesses several 
attributes that benefit gene therapy applications, including lack of pathogenicity and replication 
as well as an ability to infect dividing and non-dividing cells (9). In addition, rAAV is also capable 
of infecting a wide range of cells and maintain sustained expression (10, 11). Compared to other 
viral vectors, rAAV persists in concatemeric, episomal forms, while eliciting mild immune 
responses (12-14). The usefulness of rAAV-based delivery for gene therapy is reflected in the 
number of clinical trials involving rAAV (15). One of the most exciting advancements for rAAV 
gene therapy field has been the FDA’s recent market approval of a therapy for RPE65-mediated 
inherited retinal disease (IRD), the first of its kind in the United States (16).  
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/295055doi: bioRxiv preprint first posted online Apr. 4, 2018; 
 5 
More recently, several groups have focused their efforts on using this tool for in vivo delivery of 
Cas9 orthologs (17-20). The majority of Cas9 genome editing efforts have been focused on the 
widely-used type II-A ortholog from Streptococcus pyogenes, SpyCas9.  Although it exhibits 
consistently robust genome-editing activity, considerable effort has been required to overcome 
off-target editing activities of wild-type SpyCas9 (21-23) (Amrani et al., manuscript submitted). 
Furthermore, its large size (1,368 amino acids, 4.10 kb) restricts its delivery with its guide in a 
single virion with potent vectors such as rAAV (24). Split SpyCas9 constructs (expressed from 
separate viruses) have been employed (19), though activity is sometimes compromised (25-27). 
Dual-rAAV delivery of SpyCas9 and sgRNA can be achieved (28), but it requires the usage of 
highly minimized promoters that limit expression and tissue specificity. Furthermore, dual rAAV 
formats carry significant costs as well as limitations in co-transduction. 
Alternatively, compact Cas9 orthologs can be packaged in all-in-one rAAV vectors. Type II-A 
Staphylococcus aureus (SauCas9) (1,053 amino acids, 3.16 kb) and type II-C Campylobacter jejuni Cas9 
(CjeCas9) (984 amino acids, 2.95 kb) have been deployed successfully via rAAV in mice (18, 20). 
However, unlike the highly abundant NGG SpyCas9 PAM, these Cas9 nucleases have more 
restrictive PAM requirements (for SauCas9, 5’-NNGRRT-3’; for CjeCas9, 5’-N4RYAC (29). 
Furthermore, off-target editing by SauCas9 is not unusual (18, 30). For these reasons, many 
genomic sites of interest cannot be targeted by all-in-one rAAV delivery of the Cas9 genome 
editing machinery, and additional capabilities and PAM specificities are therefore needed. 
We and others have reported genome editing in mammalian cells by the type II-C Cas9 from 
Neisseria meningitidis strain 8013 (NmeCas9) (31-33) [Amrani et al., manuscript submitted 
(http://www.biorxiv.org/content/early/2017/08/04/172650v2)]. NmeCas9 is small (1,082 
amino acids, 3.16 kb), targets PAMs (N4GAYT > N4GYTT/N4GAYA/N4GTCT) that are 
distinct from those of the other compact Cas9 orthologs described above, and is intrinsically 
resistant to off-targeting (32) (Amrani et al., manuscript submitted). Additionally, NmeCas9 can 
be subjected to off-switch control by anti-CRISPR proteins (34), which could facilitate spatial 
and temporal control over NmeCas9 activity in vivo and ex vivo. 
In this study, we report the in vivo delivery of NmeCas9 and its guide by a single expression 
cassette that is sufficiently small for all-in-one rAAV vectors. Two disease genes were targeted 
separately to highlight the therapeutic potential of NmeCas9: the Hpd gene in a hereditary 
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tyrosinemia type I (HTI) mouse model (Fahneo), and the Pcsk9 gene in C57Bl/6 mice. Hpd encodes 
the 4-hydroxyphenylpyruvate dioxygenase enzyme in the tyrosine metabolism pathway, and 
disrupting Hpd can lead to a decrease in the accumulation of toxic fumarylacetoacetate in 
tyrosinemia models (35). Separately, Pcsk9 encodes proprotein convertase subtilisin/kexin type 9 
(PCSK9), an antagonist of the low-density lipoprotein (LDL) receptor (36, 37). When PCSK9 is 
knocked out, more LDL receptors are available at the surface of hepatocytes to allow cholesterol 
binding and recycling towards the lysosomes for degradation (38, 39). The alleviation of 
tyrosinemia symptoms upon Hpd disruption, as well as the reduced serum cholesterol levels that 
result from Pcsk9 disruption, provide convenient readouts for genome editing activity (18, 35). We 
used these systems to validate all-in-one rAAV delivery of NmeCas9 as an effective in vivo genome 
editing platform in mammals. 
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Methods 
Construction of All-in-One AAV-sgRNA-hNMeCas9 Plasmid and rAAV vector 
production 
The human-codon-optimized NmeCas9 gene under the control of the U1a promoter, and a 
single-guide RNA cassette driven by the U6 promoter, were cloned into an AAV2 plasmid 
backbone. The NmeCas9 ORF was flanked by four nuclear localization signals – two on each 
terminus – in addition to a triple-HA epitope tag. Oligonucleotides with spacer sequences 
targeting Hpd, Pcsk9, and Rosa26 were inserted into the sgRNA cassette by ligation into a SapI 
cloning site (Supplementary Note). 
AAV vector production was performed at the Horae Gene Therapy Center at the University of 
Massachusetts Medical School. Briefly, plasmids were packaged in AAV8 capsid by triple-
plasmid transfection in HEK 293 cells and purified by sedimentation as previously described (40). 
The off-target profiles of these spacers were predicted computationally using the Bioconductor 
package CRISPRseek. Search parameters were adapted to NmeCas9 settings as described 
previous (Amrani et al., manuscript submitted): gRNA.size = 24, PAM = "NNNNGATT", 
PAM.size = 8, RNA.PAM.pattern = "NNNNGNNN$", weights = c(0, 0, 0, 0, 0, 0, 0.014, 0, 0, 
0.395, 0.317, 0, 0.389, 0.079, 0.445, 0.508, 0.613, 0.851, 0.732, 0.828, 0.615, 0.804, 0.685, 
0.583), max.mismatch = 6, allowed.mismatch.PAM = 7, topN = 10000, min.score = 0. 
Cell culture and transfection 
Mouse Hepa 1-6 hepatoma cells were cultured in DMEM with 10% FBS and 1% 
Penicillin/Streptomycin (Gibco) in a 37 °C incubator with 5% CO2. Transient transfections of 
Hepa 1-6 cells were performed using Lipofectamine LTX.  For transient transfection, 
approximately 1x105 cells per well were cultured in 24-well plates 24 hours before transfection. 
Each well was transfected with 500 ng all-in-one AAV-sgRNA-hNmeCas9 plasmid, using 
Lipofectamine LTX with Plus Reagent (Invitrogen) according to the manufacturer’s protocol.  
DNA isolation from cells and liver tissue 
Genomic DNA isolation from cells was performed 72 hours post-transfection cells using DNeasy 
Blood and Tissue kit (Qiagen) following the manufacturer’s protocol. Mice were sacrificed and 
liver tissues were collected 10 days post-hydrodynamic injection or 14 and 50 days post-tail vein 
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rAAV injection. Genomic DNA was isolated using DNeasy Blood and Tissue kit (Qiagen) 
according to the manufacturer’s protocol. 
GUIDE-seq 
GUIDE-seq analysis was performed as previously described (22). Briefly, 7.5 pmol of annealed 
GUIDE-seq oligonucleotides and 500 ng of all-in-one AAV-sgRNA-hNmeCas9 plasmids 
targeting Pcsk9, Rosa26 and Hpd were transfected into 1x105 Hepa 1-6 cells using Lipofectamine 
LTX with Plus Reagent (Invitrogen). At 72 hours post-transfection, genomic DNA was extracted 
using a DNeasy Blood and Tissue kit (Qiagen) per manufacturer protocol. Library preparations, 
deep sequencing, and reads analysis were performed as previously described (41, 42). The 
Bioconductor package GUIDEseq was used for off-target analysis as described previously using 
maximum allowed mismatch of 10 nt between the guide and target DNA (41). For read 
alignment, mouse mm10 was used as a reference genome. 
Indel analysis 
TIDE primers were designed ~700 bp apart, with the forward primer at ~200 bp upstream of 
the cleavage site. 50 ng of genomic DNA was used for PCR amplification with High Fidelity 2X 
PCR Master Mix (New England Biolabs). For TIDE analysis, 30 μl of a PCR product was 
purified using QIAquick PCR Purification Kit (Qiagen) and sent for Sanger sequencing using the 
TIDE forward primer (Supplementary Table). Indel values were obtained using the TIDE 
web tool (https://tide-calculator.nki.nl/) as described previously (43). 
Targeted deep-sequencing analysis was performed for Hepa 1-6 cells and mouse liver gDNA 
using a two-step PCR amplification approach as described previously (42) (Amrani et al., 
manuscript submitted). Briefly, in the first PCR step, on-target or off-target locus-specific primers 
were used to amplify the editing site using Phusion High Fidelity DNA Polymerase (New 
England Biolabs) with a 65˚C annealing temperature. The primer ends contained sequences 
complementary to Illumina TruSeq adaptor sequences (Supplementary Table). In the 
second-step PCR, equimolar amounts of DNA were amplified with a universal forward primer 
and an indexed reverse primer using Phusion High Fidelity DNA Polymerase (98 °C, 15s; 61°C, 
25s; 72 °C, 18s; 9 cycles) to ligate the TruSeq adaptors. The resultant amplicons were separated 
in a 2.5% agarose gel and the corresponding ~250 bp product bands were extracted using 
Monarch DNA Gel Extraction Kit (New England Biolabs). 
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The libraries were then sequenced on an Illumina MiSeq in paired-end mode with a read length 
of 150 bp. To analyze genome editing outcomes at genomic sites, the command line utilities of 
CRISPResso were used (44). Input parameters were adjusted to filter low-quality reads (-q 30 -s 
20). Furthermore, the background was determined using the control sample (no guide) and 
subtracted from the experimental samples. The resulting indel frequencies, sizes and distributions 
were then plotted using Graphpad PRISM.  
Animals and liver tissue processing 
All animal procedures were reviewed and approved by The Institutional Animal Care and Use 
Committee (IACUC) at University of Massachusetts Medical School. For hydrodynamic 
injections, 2.5 mL of 30 μg of endotoxin-free AAV-sgRNA-hNmeCas9 plasmid targeting Pcsk9 or 
2.5 ml PBS was injected by tail-vein into 9- to 18-week-old female C57BL/6 mice. Mice were 
euthanized 10 days later, and liver tissue was harvested. For the AAV8 vector injections, 12- to 
16-week-old female C57BL/6 mice were injected with 4 x1011 genome copies per mouse via tail 
vein, using vectors targeting Pcsk9 or Rosa26. Mice were sacrificed 14 and 50 days after vector 
administration and liver tissues were collected for analysis. 
For Hpd targeting, 2 mL PBS or 2 mL of 30 μg of endotoxin-free AAV-sgRNA-hNmeCas9 plasmid 
was administered into 15-to 21-week-old Type 1 Tyrosinemia Fah knockout mice (Fahneo) via tail 
vein. The encoded sgRNAs targeted sites in exon 8 (sgHpd1) or exon 11 (sgHpd2). The HT1 
homozygous mice with the Fahneo allele in a 129 background were kindly provided by Dr. Markus 
Grompe (45). The HT1 mice were fed with 10 mg/L NTBC [2-(2-nitro-4-trifluoromethylbenzoyl)-
1,3-cyclohexanedione] (Sigma-Aldrich, Cat. No. PHR1731-1G) in drinking water when indicated. 
Both sexes were used in these experiments. Mice were maintained on NTBC water for 7 days post-
injection and then switched to normal water. Body weight was monitored every 1-3 days. The 
PBS-injected control mice were sacrificed when they became moribund after losing 20% of their 
body weight after removal from NTBC treatment. 
Mice were euthanized according to our protocol and liver tissue was sliced and fragments stored 
at -80°C. Some liver tissues were fixed in 4% formalin overnight, embedded in paraffin, 
sectioned and stained with hematoxylin and eosin (H&E). 
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/295055doi: bioRxiv preprint first posted online Apr. 4, 2018; 
 10 
Serum analysis 
Blood (~200 μL) was drawn from the facial vein at 0, 25 and 50 days post vector administration. 
Serum was isolated using a serum separator (BD, Cat. No. 365967) and stored under -80 °C until 
assay. 
Serum cholesterol levels were measured by Infinity™ colorimetric endpoint assay (Thermo-
Scientific) following the manufacturer’s protocol. Briefly, serial dilutions of Data-Cal™ 
Chemistry Calibrator were prepared in PBS. In a 96-well plate, 2 μL of mice sera or calibrator 
dilution was mixed with 200 μL of Infinity™ cholesterol liquid reagent, then incubated at 37 °C 
for 5 minutes. The absorbance was measured at 500 nm using a BioTek Synergy HT microplate 
reader. 
Western blot 
Liver tissue fractions were ground and resuspended in 150 μL of RIPA lysis buffer. Total protein 
content was estimated by Pierce™ BCA Protein Assay Kit (Thermo-Scientific) following the 
manufacturer’s protocol. 20 μg of protein from tissue or 2 ng of Recombinant Mouse Proprotein 
Convertase 9/PCSK9 Protein (R&D Systems, 9258-SE-020) were loaded onto a 4-20% Mini-
PROTEAN® TGX™ Precast Gel (Bio-Rad). The separated bands were transferred onto PVDF 
membrane and blocked with 5% Blocking-Grade Blocker solution (Bio-Rad) for 2 hours at room 
temperature. Membranes were incubated with rabbit anti-GAPDH (Abcam ab9485, 1:2000) or 
goat anti-PCSK9 (R&D Systems AF3985, 1:400) antibodies overnight at 4 °C. Membranes were 
washed five times in TBST and incubated with horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit (Bio-Rad 1706515, 1:4000), and donkey anti-goat (R&D Systems HAF109, 1:2000) 
secondary antibodies for 2 hours at room temperature. The membranes were washed five times 
in TBST and visualized with Clarity™ western ECL substrate (Bio-Rad) using an M35A X-
OMAT Processor (Kodak). 
Humoral Immune Response 
Humoral IgG1 immune response to NmeCas9 was measured by ELISA (Bethyl; Mouse IgG1 
ELISA Kit, E99-105) following manufacturer’s protocol with a few modifications. Briefly, 
expression and three-step purification of NmeCas9 and SpyCas9 was performed as previously 
described (4). 0.5 μg of recombinant NmeCas9 or SpyCas9 proteins suspended in 1x coating 
buffer (Bethyl) were used to coat 96-well plates (Corning), and incubated for 12 hours at 4 °C 
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with shaking. The wells were washed 3 times while shaking for 5 minutes using 1x Wash Buffer. 
Plates were blocked with 1x BSA Blocking Solution (Bethyl) for 2 hours at room temperature, 
then washed three times. Serum samples were diluted 1:40 using PBS and added to each well in 
duplicate. After incubating the samples at 4 °C for 5 hours, the plates were washed 3x times for 5 
minutes and 100 μL of biotinylated anti-mouse IgG1 antibody (Bethyl; 1: 100,000 in 1 x BSA 
Blocking Solution) was added to each well. After incubating for 1 hour at room temperature, the 
plates were washed 4 times, and 100 μL of TMB Substrate was added to each well. The plates 
were allowed to develop in the dark for 20 minutes at room temperate, and 100 μL of ELISA 
Stop Solution was then added per well. Following the development of the yellow solution, 
absorbance was recorded at 450 nm using a BioTek Synergy HT microplate reader. 
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Results 
 
Efficient Genome Editing Using All-in-One AAV-sgRNA-hNmeCas9 Plasmid in 
Cells and in vivo by Hydrodynamic Injection 
Recently, we have shown that the relatively compact NmeCas9 is active in genome editing in a 
range of cell types (Amrani et al., manuscript submitted). To exploit the small size of this Cas9 
ortholog, we generated an all-in-one AAV construct with human-codon-optimized NmeCas9 
under the expression of the mouse U1a promoter, and with its sgRNA driven by the U6 
promoter (Figure 1A; Supplementary Note).  
Two sites in the mouse genome were selected initially to test the nuclease activity of NmeCas9 in 
vivo: the Rosa26 “safe-harbor” gene (targeted by sgRosa26), and the proprotein convertase 
subtilisin/kexin type 9 (Pcsk9) gene (targeted by sgPcsk9), a common therapeutic target for 
lowering circulating cholesterol and reducing the risk of cardiovascular disease (Figure 1B). 
Genome-wide off-target predictions for these guides were determined computationally using the 
Bioconductor package CRISPRseek 1.9.1 (46) with N4GN3 PAMs and up to 6 mismatches. 
Many N4GN3 PAMS are inactive, so these search parameters are nearly certain to cast a wider 
net than the true off-target profile. Despite the expansive nature of the search, our analyses 
revealed no off-target sites with fewer than four mismatches in the mouse genome 
(Supplementary Figure 1). On-target editing efficiencies at these target sites were evaluated in 
mouse Hepa 1-6 hepatoma cells by plasmid transfections and indel quantification was performed 
by sequence trace decomposition using the TIDE web tool. We found >25% indel values for the 
selected guides, the majority of which were deletions (Figure 1C).  
To evaluate the preliminary efficacy of the constructed all-in-one AAV-sgRNA-hNmeCas9 
vector, endotoxin-free sgPcsk9 plasmid was hydrodynamically administered into the C57Bl/6 
mice via tail-vein injection. This method can deliver plasmid DNA to ~40% of hepatocytes for 
transient expression (47). Indel analyses by TIDE using DNA extracted from liver tissues 
revealed 5-9% indels 10 days after vector administration (Figure 1D), comparable to the editing 
efficiencies obtained with analogous tests of SpyCas9 (48). These results suggested that NmeCas9 
is capable of editing liver cells in vivo.  
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/295055doi: bioRxiv preprint first posted online Apr. 4, 2018; 
 13 
Knockout of 4-Hydroxyphenylpyruvate Dioxygenase Rescues the Lethal 
Phenotypes of Hereditary Tyrosinemia Type I Mice 
Hereditary Tyrosinemia type I (HT-I) is a fatal genetic disease caused by autosomal recessive 
mutations in the Fah gene, which codes for the fumarylacetoacetate hydroxylase (FAH) enzyme. 
Patients with diminished FAH have a disrupted tyrosine catabolic pathway, leading to the 
accumulation of toxic fumarylacetoacetate and succinyl acetoacetate, causing liver and kidney 
damage (49). Over the past two decades, the disease has been controlled by 2-(2-Nitro-4-
trifluoromethylbenzoyl) -1,3- cyclohexanedione (NTBC), which inhibits 4-
hydroxyphenylpyruvate dioxygenase upstream in the tyrosine degradation pathway, thus 
preventing the accumulation of the toxic metabolites (50). However, this treatment requires 
lifelong management of diet and medication, and may eventually require liver transplantation 
(51). 
Several gene therapy strategies have been tested to correct the defective Fah gene using site-
directed mutagenesis (52) or homology-directed repair by CRISPR-Cas9 (52-54). It has been 
reported that successful modification of only 1/10,000 of hepatocytes in the liver is sufficient to 
rescue the phenotypes of Fahmut/mut mice. Recently, a metabolic pathway reprogramming 
approach has been suggested in which the function of the hydroxyphenylpyruvate dioxygenase 
(HPD) enzyme was disrupted by the deletion of exons 3 and 4 of the Hpd gene in the liver (35). 
This provides us with a context in which to test the efficacy of NmeCas9 editing, by targeting 
Hpd and assessing rescue of the disease phenotype in Fah mutant mice (45). For this purpose, we 
screened and identified two target sites [one each in exon 8 (sgHpd1) and exon 11 (sgHpd2)] within 
the open reading frame of Hpd (Figure 2A). These guides induced average indel efficiencies of 
10.8% and 9.1%, respectively by plasmid transfections in Hepa 1-6 cells (Supplementary 
Figure 2). 
Three groups of mice were treated by hydrodynamic injection with either PBS, or with one of 
the two sgHpd1 and sgHpd2 all-in-one AAV-sgRNA-hNmeCas9 plasmids. One mouse in the 
sgHpd1 group and two in the sgHpd2 group were excluded from the follow-up study due to failed 
tail-vein injections. Mice were taken off NTBC-containing water 7 days after injections, and their 
weight was monitored for 43 days post-injection (Figure 2B). Mice injected with PBS suffered 
severe weight loss (a hallmark of HT-I), and were sacrificed after losing 20% of their body weight 
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(Figure 2C). Overall, all sgHpd1 and sgHpd2 mice successfully maintained their body weight for 
43 days overall, and for at least 21 days without NTBC (Figure 2C). NTBC treatment had to be 
resumed for 2-3 days for two mice that received sgHpd1 and one that received sgHpd2 to allow 
them to regain body weight during the 3rd week after plasmid injection, perhaps due to low initial 
editing efficiencies, liver injury due to hydrodynamic injection, or both. Conversely, all other 
sgHpd1 and sgHpd2 treated mice achieved indels with frequencies ranging from 35% to 60% 
(Figure 2D). This level of gene inactivation likely reflects not only the initial editing events but 
also the competitive expansion of edited cell lineages (after NTBC withdrawal) at the expense of 
their unedited counterparts (51, 52, 54). Liver histology revealed that liver damage is 
substantially less severe in the sgHpd1 and sgHpd2 treated mice compared to Fahmut/mut mice 
injected with PBS, as indicated by the smaller numbers of multinucleated hepatocytes compared 
to PBS-injected mice (Supplementary Figure 3). 
In vivo Genome Editing by NmeCas9 Delivered by a rAAV Vector 
Although plasmid hydrodynamic injections can generate indels, therapeutic development will 
require less invasive delivery strategies, such as rAAV. To this end, all-in-one AAV-sgRNA-
hNmeCas9 plasmids were packaged in hepatocyte-tropic AAV8 capsids to target Pcsk9 (sgPcsk9) 
and Rosa26 (sgRosa26) (Figure 1B) (55, 56). Vectors were administered into C57BL/6 mice via 
tail vein (Figure 3A). We monitored cholesterol level in the serum, and measured PCSK9 
protein and indel frequencies in the liver tissues 25 and 50 days post injection. 
Using a colorimetric endpoint assay, we determined that the circulating serum cholesterol level in 
the sgPcsk9 mice decreased significantly (p < 0.001) compared to the PBS and sgRosa26 mice at 25 
and 50 days post-injection (Figure 3B). Targeted deep-sequencing analyses at Pcsk9 and Rosa26 
target sites revealed very efficient indels of 35% and 55% respectively at 50 days post-vector 
administration (Figure 3C). Additionally, one mouse of each group was euthanized at 14 days 
post-injection, and revealed on-target indel efficiencies of 37% and 46% at Pcsk9 and Rosa26, 
respectively (Figure 3C). As expected, PCSK9 protein levels in the livers of sgPcsk9 mice were 
substantially reduced compared to the mice injected with PBS and sgRosa26 (Figure 3D). The 
efficient editing, PCSK9 reduction, and diminished serum cholesterol indicate the successful 
delivery and activity of NmeCas9 at the Pcsk9 locus.  
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SpyCas9 delivered by viral vectors is known to elicit host immune responses (19, 57). To 
investigate if the mice injected with AAV8-sgRNA-hNmeCas9 generate anti-NmeCas9 
antibodies, we used sera from the treated animals to perform IgG1 ELISA. Our results show that 
NmeCas9 elicits a humoral response in these animals (Supplementary Figure 4). Despite the 
presence of an immune response, NmeCas9 delivered by rAAV is highly functional in vivo, with 
no apparent signs of abnormalities or liver damage (Supplementary Figure 5). 
NmeCas9 is Highly Specific in vivo 
A significant concern in therapeutic CRISPR/Cas9 genome editing is the possibility of off-target 
edits. We and others have found that wildtype NmeCas9 is a naturally high-accuracy genome 
editing platform in cultured mammalian cells (32) (Amrani et al., manuscript submitted). To 
determine if NmeCas9 maintains its minimal off-targeting profile in mouse cells and in vivo, we 
screened for off-target sites in the mouse genome using genome-wide, unbiased identification of 
DSBs enabled by sequencing (GUIDE-seq) (22). Hepa 1-6 cells were transfected with sgPcsk9, 
sgRosa26, sgHpd1 and sgHpd2 all-in-one AAV-sgRNA-hNmeCas9 plasmids and the resulting 
genomic DNA was subjected to GUIDE-seq analysis. Consistent with our previous observations 
in human cells (Amrani et al., manuscript submitted), GUIDE-seq revealed very few off-target 
(OT) sites in the mouse genome. Four potential OT sites were identified for sgPcsk9 and another 
six for sgRosa26. We were unable to detect off-target edits with sgHpd1 and sgHpd2 (Figure 4A), 
thus reinforcing our previous observation that NmeCas9 is often intrinsically hyper-accurate 
(Amrani et al., manuscript submitted). 
Several of the putative OT sites for sgPcsk9 and sgRosa26 lack the NmeCas9 PAM preferences 
(N4GATT, N4GCTT, N4GTTT, N4GACT, N4GATA, N4GTCT, and N4GACA) (Figure 4B) 
and may therefore represent background. To validate these OT sites, we performed targeted 
deep-sequencing using genomic DNA from Hepa 1-6 cells. By this more sensitive readout, indels 
were undetectable above background at all these OT sites except OT1 of Pcsk9, which had an 
indel frequency less than 2% (Figure 4B). To validate NmeCas9’s high fidelity in vivo, we 
measured indel formation at these OT sites in liver genomic DNA from the AAV8-NmeCas9-
treated, sgPcsk9- and sgRosa26-targeted mice. We found little or no detectable off-target editing in 
mice liver sacrificed at 14 days at all sites except sgPcsk9 OT1, which exhibited fewer than 2% 
lesion efficiency (Figure 4C). More importantly, this level of OT editing stayed below <2% even 
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after 50 days, and also remained either undetectable or very low for all other candidate OT sites. 
These results suggested that extended (50 days) expression of NmeCas9 in vivo does not 
compromise its targeting fidelity (Figure 4C). 
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Discussion 
 
All-in-One rAAV delivery of hNmeCas9 
Compared to transcription activator-like effector nucleases (TALENs) and Zinc-finger nucleases 
(ZFNs), Cas9s are distinguished by their flexibility and versatility (1). Such characteristics make 
them ideal for driving the field of genome engineering forward. Over the past few years, 
CRISPR-Cas9 has been used to enhance products in agriculture, food and industry, in addition 
to the promising applications in gene therapy and personalized medicine (58). Despite the 
diversity of Class 2 CRISPR systems that have been described, only a handful of them have been 
developed and validated for genome editing in vivo. In this study, we have shown that NmeCas9 is 
a compact, high-fidelity Cas9 that can be considered for future in vivo genome editing 
applications using all-in-one rAAV. Its unique PAM enables editing at additional targets that are 
inaccessible to the other two compact, all-in-one rAAV-validated orthologs (SauCas9 and 
CjeCas9).  
 
Therapeutic Gene Correction for Hereditary Tyrosinemia Type 1 by Metabolic 
Pathway Reprograming 
Patients with mutations in the HPD gene are considered to have Type III Tyrosinemia and 
exhibit high level of tyrosine in blood, but otherwise appear to be largely asymptomatic (59, 60). 
HPD acts upstream of FAH in the tyrosine catabolism pathway, and Hpd disruption ameliorates 
HT-I symptoms by preventing the toxic metabolite buildup that results from loss of FAH. 
Structural analyses of HPD reveal that the catalytic domain of the HPD enzyme is located at the 
C-terminus of the enzyme and encoded by exon 13 and 14 (61). Thus, frameshift-inducing indels 
upstream of exon 13 should render the enzyme inactive. We used this context to demonstrate 
that Hpd inactivation by hydrodynamic injection of NmeCas9 plasmid is a viable approach to 
rescue HT-I mice. NmeCas9 can edit sites carrying several different PAMs [N4GATT 
(consensus), N4GCTT, N4GTTT, N4GACT, N4GATA, N4GTCT, and N4GACA] (Amrani et al., 
manuscript submitted). Our Hpd editing experiments confirmed one of the variant PAMs in vivo 
with the sgHpd2 guide, which targets a site with a N4GACT PAM.  
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Efficient, Accurate NmeCas9 Genome Editing with rAAV Delivery 
To achieve targeted delivery of NmeCas9 to various tissues in vivo, rAAV vectors are a promising 
delivery platform due to the compact size of NmeCas9 transgene, which allows the delivery of 
NmeCas9 and its guide in all-in-one format. We have validated this approach for the targeting of 
Pcsk9 and Rosa26 genes in adult mice, with efficient editing observed even at 14 days post-
injection. As observed previously in cultured cells (32) (Amrani et al., manuscript submitted), 
NmeCas9 is intrinsically accurate, even without the extensive engineering that was required to 
reduce off-targeting by SpyCas9 (21-23). We performed side-by-side comparisons of NmeCas9 
OT editing in cultured cells and in vivo by targeted deep-sequencing, and we found that off-
targeting is minimal in both settings. Editing at the sgPcsk9 OT1 site (within an unannotated 
locus) was the highest detectable at ~2%. Despite these promising results, more extensive and 
long-term studies, including in larger animals, will be needed to fully understand the long-term 
effects of Cas9 expression in tissues, as well as the development of approaches that clear viral 
vectors after editing is complete.  
In conclusion, we demonstrate that NmeCas9 is amenable to in vivo genome editing using the 
highly desirable all-in-one rAAV platform. With its unique PAM preferences and high fidelity, 
this all-in-one AAV-sgRNA-hNeCas9 can be applied to a range of genome editing purposes in 
vivo. 
 
  
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/295055doi: bioRxiv preprint first posted online Apr. 4, 2018; 
 19 
Acknowledgments 
We thank Haiwei Mou and Yueying Cao for assistance with mouse injections, and Xin Gao for 
assistance in designing of deep sequencing and GUIDE-seq libraries. We also thank the UMMS 
Viral Vector Core for AAV packaging services, and the UMMS Deep Sequencing Core for 
sequencing. We are grateful to Guangping Gao, Scot Wolfe, and all members of the Xue and 
Sontheimer labs for discussions, advice, and helpful feedback. W.X. was supported by the NIH 
(DP2HL137167 and P01HL131471), the Lung Cancer Research Foundation, the ALS 
Association, the American Cancer Society (129056-RSG-16-093), and Hyundai Hope on 
Wheels. E.J.S. was supported by the NIH (R01GM1115911 to Scot A. Wolfe and E.J.S.). E.J.S. 
is a co-founder and advisor of Intellia Therapeutics, Inc. 
 
 
Author Contributions 
R.I. and E.J.S. initiated the study, and R.I., C.S., W.X. and E.J.S. designed experiments. R.I. 
designed, constructed, and validated all-in-one AAV-sgRNA-hNmeCas9 plasmids in cells, 
prepared GUIDE-seq and targeted lesion libraries from cultured cells and mouse tissues, and 
analyzed in vivo-edited samples. C.S. performed mouse manipulations including plasmid 
hydrodynamic injections, AAV injections, and serum and animal tissue collection. N.A. provided 
assistance with construct design and GUIDE-seq library preparation. A.M. analyzed deep-
sequencing and GUIDE-seq datasets. R.I., A.M., and E.J.S. wrote the manuscript, and all 
authors edited the manuscript. 
  
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/295055doi: bioRxiv preprint first posted online Apr. 4, 2018; 
 20 
References 
1. Komor AC, Badran AH, & Liu DR (2017) CRISPR-Based Technologies for the 
Manipulation of Eukaryotic Genomes. Cell 168(1-2):20-36. 
2. Sontheimer EJ & Barrangou R (2015) The Bacterial Origins of the CRISPR Genome-
Editing Revolution. Hum Gene Ther 26(7):413-424. 
3. Hille F, et al. (2018) The Biology of CRISPR-Cas: Backward and Forward. Cell 
172(6):1239-1259. 
4. Jinek M, et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive 
bacterial immunity. Science 337(6096):816-821. 
5. Yin H, Kauffman KJ, & Anderson DG (2017) Delivery technologies for genome editing. 
Nat Rev Drug Discov 16(6):387-399. 
6. Wong JKL, et al. (2017) Limitations in Clinical Translation of Nanoparticle-Based Gene 
Therapy. Trends Biotechnol 35(12):1124-1125. 
7. Lee K, et al. (2017) Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in 
vivo induces homology-directed DNA repair. Nature Biomedical Engineering 1(11):889-901. 
8. Yin H, et al. (2017) Structure-guided chemical modification of guide RNA enables potent 
non-viral in vivo genome editing. Nature Biotechnology 35:1179. 
9. Grieger JC & Samulski RJ (2012) Adeno-associated virus vectorology, manufacturing, 
and clinical applications. Methods Enzymol 507:229-254. 
10. Vassalli G, Bueler H, Dudler J, von Segesser LK, & Kappenberger L (2003) Adeno-
associated virus (AAV) vectors achieve prolonged transgene expression in mouse 
myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J 
Cardiol 90(2-3):229-238. 
11. Zincarelli C, Soltys S, Rengo G, & Rabinowitz JE (2008) Analysis of AAV serotypes 1-9 
mediated gene expression and tropism in mice after systemic injection. Mol Ther 
16(6):1073-1080. 
12. Penaud-Budloo M, et al. (2008) Adeno-associated virus vector genomes persist as episomal 
chromatin in primate muscle. J Virol 82(16):7875-7885. 
13. Nayak S & Herzog RW (2010) Progress and prospects: immune responses to viral vectors. 
Gene Ther 17(3):295-304. 
14. Sack BK & Herzog RW (2009) Evading the immune response upon in vivo gene therapy 
with viral vectors. Curr Opin Mol Ther 11(5):493-503. 
15. Keeler AM, ElMallah MK, & Flotte TR (2017) Gene Therapy 2017: Progress and Future 
Directions. Clin Transl Sci 10(4):242-248. 
16. Bennett J, et al. (2016) Safety and durability of effect of contralateral-eye administration of 
AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 
mutations: a follow-on phase 1 trial. Lancet 388(10045):661-672. 
17. Swiech L, et al. (2015) In vivo interrogation of gene function in the mammalian brain 
using CRISPR-Cas9. Nat Biotechnol 33(1):102-106. 
18. Ran FA, et al. (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 
520(7546):186-191. 
19. Chew WL, et al. (2016) A multifunctional AAV-CRISPR-Cas9 and its host response. Nat 
Methods 13(10):868-874. 
20. Kim E, et al. (2017) In vivo genome editing with a small Cas9 orthologue derived from 
Campylobacter jejuni. Nat Commun 8:14500. 
21. Bolukbasi MF, Gupta A, & Wolfe SA (2016) Creating and evaluating accurate CRISPR-
Cas9 scalpels for genomic surgery. Nat Methods 13(1):41-50. 
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/295055doi: bioRxiv preprint first posted online Apr. 4, 2018; 
 21 
22. Tsai SQ & Joung JK (2016) Defining and improving the genome-wide specificities of 
CRISPR-Cas9 nucleases. Nat Rev Genet 17(5):300-312. 
23. Tycko J, Myer VE, & Hsu PD (2016) Methods for Optimizing CRISPR-Cas9 Genome 
Editing Specificity. Mol Cell 63(3):355-370. 
24. Wu Z, Yang H, & Colosi P (2010) Effect of genome size on AAV vector packaging. Mol 
Ther 18(1):80-86. 
25. Wright AV, et al. (2015) Rational design of a split-Cas9 enzyme complex. Proc Natl Acad Sci 
U S A 112(10):2984-2989. 
26. Zetsche B, Volz SE, & Zhang F (2015) A split-Cas9 architecture for inducible genome 
editing and transcription modulation. Nat Biotechnol 33(2):139-142. 
27. Truong DJ, et al. (2015) Development of an intein-mediated split-Cas9 system for gene 
therapy. Nucleic Acids Res 43(13):6450-6458. 
28. Suzuki K, et al. (2016) In vivo genome editing via CRISPR/Cas9 mediated homology-
independent targeted integration. Nature 540(7631):144-149. 
29. Mir A, Edraki A, Lee J, & Sontheimer EJ (2018) Type II-C CRISPR-Cas9 Biology, 
Mechanism, and Application. ACS Chem Biol 13(2):357-365. 
30. Friedland AE, et al. (2015) Characterization of Staphylococcus aureus Cas9: a smaller 
Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. 
Genome Biol 16:257. 
31. Esvelt KM, et al. (2013) Orthogonal Cas9 proteins for RNA-guided gene regulation and 
editing. Nat Methods 10(11):1116-1121. 
32. Lee CM, Cradick TJ, & Bao G (2016) The Neisseria meningitidis CRISPR-Cas9 System 
Enables Specific Genome Editing in Mammalian Cells. Mol Ther 24(3):645-654. 
33. Hou Z, et al. (2013) Efficient genome engineering in human pluripotent stem cells using 
Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A 110(39):15644-15649. 
34. Pawluk A, et al. (2016) Naturally Occurring Off-Switches for CRISPR-Cas9. Cell 
167(7):1829-1838 e1829. 
35. Pankowicz FP, et al. (2016) Reprogramming metabolic pathways in vivo with 
CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun 7:12642. 
36. Mousavi SA, Berge KE, & Leren TP (2009) The unique role of proprotein convertase 
subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med 266(6):507-519. 
37. Lagace TA (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation 
and in cells. Curr Opin Lipidol 25(5):387-393. 
38. Fitzgerald K, et al. (2017) A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N 
Engl J Med 376(1):41-51. 
39. Rashid S, et al. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice 
lacking Pcsk9. Proc Natl Acad Sci U S A 102(15):5374-5379. 
40. Gao GP & Sena-Esteves M (2012) Introducing Genes into Mammalian Cells: Viral 
Vectors. Molecular Cloning: A Laboratory Manual, eds Green MR & Sambrook J (Cold Spring 
Harbor Laboratory Press, New York), 4th Ed Vol 2, pp 1209-1313. 
41. Zhu LJ, et al. (2017) GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets 
for CRISPR-Cas nucleases. BMC Genomics 18(1):379. 
42. Bolukbasi MF, et al. (2015) DNA-binding-domain fusions enhance the targeting range and 
precision of Cas9. Nat Methods 12(12):1150-1156. 
43. Brinkman EK, Chen T, Amendola M, & van Steensel B (2014) Easy quantitative 
assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 
42(22):e168. 
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/295055doi: bioRxiv preprint first posted online Apr. 4, 2018; 
 22 
44. Pinello L, et al. (2016) Analyzing CRISPR genome-editing experiments with 
CRISPResso. Nat Biotechnol 34(7):695-697. 
45. Grompe M, et al. (1993) Loss of fumarylacetoacetate hydrolase is responsible for the 
neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 7(12A):2298-
2307. 
46. Zhu LJ, Holmes BR, Aronin N, & Brodsky MH (2014) CRISPRseek: a bioconductor 
package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing 
systems. PLoS One 9(9):e108424. 
47. Liu F, Song Y, & Liu D (1999) Hydrodynamics-based transfection in animals by systemic 
administration of plasmid DNA. Gene Ther 6(7):1258-1266. 
48. Xue W, et al. (2014) CRISPR-mediated direct mutation of cancer genes in the mouse 
liver. Nature 514(7522):380-384. 
49. Grompe M (2001) The pathophysiology and treatment of hereditary tyrosinemia type 1. 
Semin Liver Dis 21(4):563-571. 
50. Lindstedt S, Holme E, Lock EA, Hjalmarson O, & Strandvik B (1992) Treatment of 
hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. 
Lancet 340(8823):813-817. 
51. Das AM (2017) Clinical utility of nitisinone for the treatment of hereditary tyrosinemia 
type-1 (HT-1). Appl Clin Genet 10:43-48. 
52. Paulk NK, et al. (2010) Adeno-associated virus gene repair corrects a mouse model of 
hereditary tyrosinemia in vivo. Hepatology 51(4):1200-1208. 
53. Yin H, et al. (2016) Therapeutic genome editing by combined viral and non-viral delivery 
of CRISPR system components in vivo. Nat Biotechnol 34(3):328-333. 
54. Yin H, et al. (2014) Genome editing with Cas9 in adult mice corrects a disease mutation 
and phenotype. Nat Biotechnol 32(6):551-553. 
55. Gao GP, et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for 
human gene therapy. Proc Natl Acad Sci U S A 99(18):11854-11859. 
56. Nakai H, et al. (2005) Unrestricted hepatocyte transduction with adeno-associated virus 
serotype 8 vectors in mice. J Virol 79(1):214-224. 
57. Wang D, et al. (2015) Adenovirus-Mediated Somatic Genome Editing of Pten by 
CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene 
Ther 26(7):432-442. 
58. Barrangou R & Doudna JA (2016) Applications of CRISPR technologies in research and 
beyond. Nat Biotechnol 34(9):933-941. 
59. Szymanska E, et al. (2015) Tyrosinemia type III in an asymptomatic girl. Mol Genet Metab 
Rep 5:48-50. 
60. Nakamura K, Tanaka Y, Mitsubuchi H, & Endo F (2007) Animal models of tyrosinemia. 
J Nutr 137(6 Suppl 1):1556S-1560S; discussion 1573S-1575S. 
61. Huang CW, et al. (2016) The different catalytic roles of the metal-binding ligands in 
human 4-hydroxyphenylpyruvate dioxygenase. Biochem J 473(9):1179-1189. 
 
  
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/295055doi: bioRxiv preprint first posted online Apr. 4, 2018; 
 23 
Figure Legends 
 
Figure 1: Validation of an all-in-one AAV-sgRNA-hNmeCas9 construct. (A) Schematic 
representation of a single rAAV vector expressing human-codon-optimized NmeCas9 and its 
sgRNA. The backbone is flanked by AAV inverted terminal repeats (ITR). The poly(A) signal is 
from rabbit beta-globin (BGH). (B) Schematic diagram of the Pcsk9 (top) and Rosa26 (bottom) 
mouse genes. Red bars represent exons. Zoomed-in views show the protospacer sequence (red) 
whereas the NmeCas9 PAM sequence is highlighted in green. Double-stranded break location 
sites are denoted (black arrowheads). (C) Stacked histogram showing the percentage distribution 
of insertions-deletions (indels) obtained by TIDE after AAV-sgRNA-hNmeCas9 plasmid 
transfections in Hepa 1-6 cells targeting Pcsk9 (sgPcsk9) and Rosa26 (sgRosa26) genes. Data are 
presented as mean values ± SD from three biological replicates. (D) Stacked histogram showing 
the percentage distribution of indels at Pcsk9 in the liver of C57Bl/6 mice obtained by TIDE 
after hydrodynamic injection of AAV-sgRNA-hNmeCas9 plasmid. 
 
Figure 2: NmeCas9-mediated knockout of Hpd rescues the lethal phenotype in Hereditary 
Tyrosinemia Type I Mice. (A) Schematic diagram of the Hpd mouse gene. Red bars represent 
exons. Zoomed-in views show the protospacer sequences (red) for targeting exon 8 (sgHpd1) and 
exon 11 (sgHpd2). NmeCas9 PAM sequences are in green, and double-stranded break locations 
are indicated (black arrowheads). (B) Experimental design. Three groups of Hereditary 
Tyrosinemia Type I Fah-/- mice are injected with PBS, or all-in-one AAV-sgRNA-hNmeCas9 
plasmids sgHpd1 or sgHpd2. (C) Weight of mice hydrodynamically injected with PBS (green), 
AAV-sgRNA-hNmeCas9 plasmid sgHpd1 targeting Hpd exon 8 (red) or sgHpd2 targeting Hpd 
exon 11 (blue) were monitored after NTBC withdrawal. Error bars represent three mice for PBS 
and sgHpd1 groups, and two mice for the sgHpd2 group. Data are presented as mean ± SD. (D) 
Stacked histogram showing the percentage distribution of indels at Hpd in liver of Fah-/- mice 
obtained by TIDE after hydrodynamic injection of PBS, or sgHpd1 and sgHpd2 plasmids. Livers 
were harvested at the end of NTBC withdrawal (day 43). 
Figure 3: AAV-delivery of NmeCas9 for in vivo genome editing. (A) Experimental outline of 
AAV8-sgRNA-hNmeCas9 vector tail-vein injections to target Pcsk9 (sgPcsk9) and Rosa26 
(sgRosa26) in C57Bl/6 mice. Mice were sacrificed at 14 (n = 1) or 50 days (n = 5) post-injection 
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and liver tissues were harvested. Blood sera were collected at day 0, 25 and 50 post-injection for 
cholesterol level measurement. (B) Serum cholesterol levels. P values are calculated by unpaired t 
test. (C) Stacked histogram showing the percentage distribution of indels at Pcsk9 or Rosa26 in 
livers of mice, as measured by targeted deep-sequencing analyses. Data are presented as mean ± 
SD from five mice per cohort. (D) A representative anti-PCSK9 western blot using total protein 
collected from day 50 mouse liver homogenates. 2 ng of recombinant mouse PCSK9 (r-PCSK9) 
was included as a mobility standard. The asterisk indicates a cross-reacting protein that is larger 
than the control recombinant protein. 
Figure 4: GUIDE-seq genome-wide specificities of NmeCas9. (A) Number of GUIDE-seq reads 
for the on-target (OnT) and off-target (OT) sites. (B) Targeted deep-sequencing to measure the 
lesion rates at each of the OT sites in Hepa 1-6 cells. The mismatches of each OT site with the 
OnT protospacers is highlighted (blue). Data are presented as mean ± SD from three biological 
replicates. (C) Targeted deep sequencing to measure the lesion rates at each of the OT sites 
using genomic DNA obtained from mice injected with all-in-one AAV8-sgRNA-hNmeCas9 
sgPcsk9 and sgRosa26 and sacrificed at day 14 (D14) or day 50 (D50) post-injection. Data are 
presented as mean ± SD. 
Supplementary Figure 1: Genome-wide computational prediction of NmeCas9 off-target 
sites using CRISPRseek with the N4GN3 PAM. Search parameters were set to identify sites with 
up to 6 mismatches to the spacer sequence. The total number of detected off-target sites for each 
protospacer is indicated. 
Supplementary Figure 2: Stacked histogram showing the percentage distribution of indels 
obtained by TIDE after AAV-sgRNA-hNmeCas9 plasmids transfections in Hepa 1-6. Error bars 
represent three independent experiments. Data are presented as mean ± SD. 
Supplementary Figure 3: H&E staining from wild-type (Fah+/+) mouse, and HT-I mice (Fah-
/-) injected with PBS or AAV-sgRNA-hNmeCas9 plasmids sgHpd1 or sgHpd2. Scale bar is 20 μm. 
Supplementary Figure 4: Humoral IgG1 immune response to NmeCas9 in vivo. Serum 
collected at day 50 post-injection with all-in-one AAV8-sgRNA-hNmeCas9 sgPcsk9 and sgRosa26. 
Serum antibodies reacted against NmeCas9 protein (left) or SpyCas9 protein (right). 
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Supplementary Figure 5: H&E staining from PBS, sgPcsk9 and sgRosa26 AAV8 injected mice. 
Scale bar is 20 μm. 
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Name Gene Chr Protospacer Sequence
sgHpd1 Hpd chr5:-:123178208:123178239 ATCAACTACACTGGCCGTTTCTTACCTGGATT
sgHpd2 Hpd chr5:-:123175950:123175981 TTGTTTCCCCTCCTCCCAGGAATATGTGGACT
sgPcsk9 Pcsk9 chr4:-:106463790:106463821 CGGCGCTGGTGCCCAGGACGAGGATGGAGATT
sgRosa26 Rosa26 chr6:+:113076048:113076079 TGCAGATCACGAGGGAAGAGGGGGAAGGGATT
sgPcsk9_OT1 unannotated chr6:-:24894402:24894433 GGCGCTGTGTGTCCTGGACGAGGAACTGGACT
sgPcsk9_OT2 Rnf214 chr9:+:45868164:45868195 AGGAACTGGAGCAAAGGACAAggagatggttt
sgPcsk9_OT3 Pcsk9 chr4:-:106463561:106463592 AGGTGCGGGAGGCGAGGGCAAGACTTAGTGCT
sgPcsk9_OT4 unannotated chr16:+:47959998:47960029 AGGGAACTGGGACCAGGACAAGGAGCTTGATT
sgRosa26_OT1 Ptcd2 chr13:-:99335395:99335426 gtcataacaccagggaagaggaggcctggatt
sgRosa26_OT2 unannotated chr1:-:96248259:96248290 TGGCAGAACagagggaagagagggggagggat
sgRosa26_OT3 Tctn3 chr19:-:40606453:40606484 AGCAGATCAGAGGGAAGAGGGAGGGGTGGAGA
sgRosa26_OT4 unannotated chr3:-:121042039:121042070 TACACATCTCTGAGGGTGATGGGCTTGGGGCT
sgRosa26_OT5 unannotated chr10:-:8135358:8135389 TGCAGAGGTTTACAAACggggggggggggggg
sgRosa26_OT6 Sergef chr7:-:46544656:46544687 gccagaagaccaggtaggacttggacgacaag
SUPPLEMENTARY TABLE
Protospacer sequences
Target Site 5’ Primer 3’ Primer
sgHpd1 GGCAGGTAGTCGAACATTCC CAGCCGTGGTTAACTGAACA
sgHpd2 CTGTGGTGTGCATGATGTC CAGCAAAATACCAGCGG
sgPcsk9 GGCTCCCGTTCTCTCTCTCT CGCTAAATCGAGGCCTACAG
sgRosa26 TCAGTTGGGCTGTTTTGGAG TAGGGGTTGGATAAGCCAGT
TIDE Primers
Target Site 5' Primer 3' Primer
sgPcsk9 ctacacgacgctcttccgatctGCTACTGTGCCCCACCGG agacgtgtgctcttccgatctCTCATCAGCCAGGCCATC
sgPcsk9_OT1 ctacacgacgctcttccgatctGTGAGGTGCCAGAGTGGTGT agacgtgtgctcttccgatctGGCTGTCAGGGTGAGAAGTG
sgPcsk9_OT2 ctacacgacgctcttccgatctCGACAAAAGAGATGAGGAGAAAA agacgtgtgctcttccgatctTGAACTCAAGTCCTTATGCTTGC
sgPcsk9_OT3 ctacacgacgctcttccgatctCCTCCCCCATCACTCTGTG agacgtgtgctcttccgatctTCTAGCCGTCTGGTGGTCTC
sgPcsk9_OT4 ctacacgacgctcttccgatctTTTGAAATGCAATCATAGCACA agacgtgtgctcttccgatctGAGACAGTAGAGCAGAATGAAGGA
sgRosa26 ctacacgacgctcttccgatctCTTCTGAGGACCGCCCT agacgtgtgctcttccgatctGCCTTTAAGCCTGCCCAG
sgRosa26_OT1 ctacacgacgctcttccgatctCACTGGCTTGGAACACACAA agacgtgtgctcttccgatctGCCCACGGTTTCAGAAAGTA
sgRosa26_OT2 ctacacgacgctcttccgatctTCTCTGCCATTTCCTCTTCC agacgtgtgctcttccgatctAAGCCCATGATTTTGTGAAA
sgRosa26_OT3 ctacacgacgctcttccgatctATGGAGAAGCCTCCCTTCAC agacgtgtgctcttccgatctCCCTAAGTTTAACCCTCAGCA
sgRosa26_OT4 ctacacgacgctcttccgatctGACAAATATGAGTTTTTACTACCAGGA agacgtgtgctcttccgatctCGTCTTAATGAGCCCGATCT
sgRosa26_OT5 ctacacgacgctcttccgatctTCAGGAAACACTTCCGCTTC agacgtgtgctcttccgatctCCGAACATCAGGATGTGAAA
sgRosa26_OT6 ctacacgacgctcttccgatctGAGCTTTCTGCCTCTGTGCT agacgtgtgctcttccgatctGGAGGAGGTGCTATCTGTGC
Deep-sequencing Primers
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SUPPLEMENTARY NOTE
Nucleotide sequence of all-in-one AAV-sgRNA-hNMeCas9 Plasmid
Legend: sgRNA scaffold GUIDE sequence U6 promoter U1a promoter NLS NLS hNmeCas9 NLS 3X-HA NLS BGH-pA
gtttaaacaaaaaaataaacgatgccccttaaagcagaagctttaaggggcagagcgttgcggcacatcttttcagacggcctt
attgtagcaacggttctcatttcgtttccgaaatgagaaagggagctacaacNNNNNNNNNNNNNNNNNNNNNNNCggtgtttc
gtcctttccacaagatatataaagccaagaaatcgaaatactttcaagttacggtaagcatatgatagtccattttaaaacata
attttaaaactgcaaactacccaagaaattattactttctacgtcacgtattttgtactaatatctttgtgtttacagtcaaat
taattctaattatctctctaacagccttgtatcgtatatgcaaatatgaaggaatcatgggaaataggccctcttcctgcccga
ccttgacgtcgactctagaatggaggcggtactatgtagatgagaattcaggagcaaactgggaaaagcaactgcttccaaata
tttgtgatttttacagtgtagttttggaaaaactcttagcctaccaattcttctaagtgttttaaaatgtgggagccagtacac
atgaagttatagagtgttttaatgaggcttaaatatttaccgtaactatgaaatgctacgcatatcatgctgttcaggctccgt
ggccacgcaactcatacttaagcagacagtggttcaaagtttttttcttccatttcaggtgtcgtgaacaccgccaccatggtg
cctaagaagaagagaaaggtggaagataaacgcccagcagctacaaagaaggcaggtcaagccaagaaaaagaaagcagcattc
aagccaaactcaatcaattacatcctgggactggacatcggcatcgcatccgtcgggtgggctatggtcgaaatcgacgaggag
gagaaccccatccgcctgatcgatctgggcgtgcgcgtgtttgagagggcagaggtgcctaagaccggcgacagcctggccatg
gcacggagactggcacgctccgtgaggcgcctgacccggagaagggcccacagactgctgaggacacgccggctgctgaagagg
gagggcgtgctgcaggccgccaacttcgatgagaatggcctgatcaagtccctgcccaataccccttggcagctgagggcagcc
gccctggaccgcaagctgacacctctggagtggtccgccgtgctgctgcacctgatcaagcaccggggctacctgtctcagaga
aagaacgagggcgagacagccgataaggagctgggcgccctgctgaagggagtggcaggaaatgcacacgccctgcagaccggc
gactttcgcacaccagccgagctggccctgaacaagttcgagaaggagagcggccacatccgcaatcagcggtctgactatagc
cacaccttctcccggaaggatctgcaggccgagctgatcctgctgtttgagaagcagaaggagttcggcaacccacacgtgtct
ggcggcctgaaggagggcatcgagacactgctgatgacacagcggcccgccctgagcggcgacgcagtgcagaagatgctggga
cactgcacctttgagccagccgagcccaaggccgccaagaatacctacacagccgagcggttcatctggctgacaaagctgaac
aatctgaggatcctggagcagggaagcgagcgcccactgaccgacacagagagggccaccctgatggatgagccctaccgcaag
tccaagctgacatatgcacaggcaaggaagctgctgggcctggaggacaccgccttctttaagggcctgagatacggcaaggat
aacgccgaggcctctacactgatggagatgaaggcctatcacgccatcagcagggccctggagaaggagggcctgaaggacaag
aagtccccactgaatctgtctcccgagctgcaggatgagatcggcaccgcctttagcctgttcaagaccgacgaggatatcaca
ggcagactgaaggacaggatccagccagagatcctggaggccctgctgaagcacatcagctttgataagttcgtgcagatcagc
ctgaaggccctgcggaggatcgtgccactgatggagcagggcaagaggtacgacgaggcctgcgccgaaatctacggcgatcac
tatggcaagaagaacacagaggagaaaatctacctgccccctatccccgccgatgagatcaggaaccctgtggtgctgcgcgcc
ctgtctcaggcaagaaaagtgatcaacggagtggtgcgccggtacggcagccccgccagaatccacatcgagacagccagggaa
gtgggcaagtcctttaaggacagaaaggagatcgagaagaggcaggaggagaacagaaaggatagggagaaggccgccgccaag
ttcagagagtactttcctaatttcgtgggcgagccaaagtccaaggatatcctgaagctgaggctgtacgagcagcagcacggc
aagtgtctgtattctggcaaggagatcaacctgggccgcctgaatgagaagggctatgtggagatcgaccacgccctgcctttt
tctcggacctgggacgatagcttcaacaataaggtgctggtgctgggctctgagaaccagaataagggcaaccagacaccctac
gagtatttcaacggcaaggacaatagccgcgagtggcaggagtttaaggcaagggtggagacaagcaggttccctcggtccaag
aagcagagaatcctgctgcagaagtttgacgaggatggcttcaaggagaggaacctgaatgacacccgctacgtgaatcggttt
ctgtgccagttcgtggccgatagaatgaggctgaccggcaagggcaagaagagagtgtttgcctccaacggccagatcacaaat
ctgctgaggggcttctggggcctgagaaaggtgagggcagagaacgacaggcaccacgcactggatgcagtggtggtggcatgt
tctaccgtggccatgcagcagaagatcacacgctttgtgcggtataaggagatgaatgccttcgacggcaagaccatcgataag
gagacaggcgaggtgctgcaccagaagacacactttcctcagccatgggagttctttgcccaggaagtgatgatccgggtgttt
ggcaagcctgacggcaagccagagttcgaggaggccgataccctggagaagctgagaacactgctggcagagaagctgagctcc
aggcccgaggcagtgcacgagtacgtgaccccactgttcgtgtctagagcccccaacaggaagatgagcggccagggccacatg
gagacagtgaagtccgccaagagactggacgagggcgtgtctgtgctgagggtgcctctgacacagctgaagctgaaggatctg
gagaagatggtgaatcgcgagcgggagccaaagctgtatgaggccctgaaggcaaggctggaggcacacaaggacgatcctgcc
aaggcctttgccgagccattctacaagtatgataaggccggcaacagaacccagcaggtgaaggccgtgagggtggagcaggtg
cagaagacaggcgtgtgggtgcgcaaccacaatggcatcgccgacaatgctaccatggtgcgggtggacgtgtttgagaagggc
gataagtactatctggtgcccatctacagctggcaggtggccaagggcatcctgcctgatagagccgtggtgcagggcaaggac
gaggaggattggcagctgatcgacgattccttcaactttaagttctctctgcaccccaatgacctggtggaagtgatcaccaag
aaggccaggatgtttggctacttcgcctcctgccaccgcggcacaggcaacatcaatatccggatccacgacctggatcacaag
atcggcaagaacggcatcctggagggcatcggcgtgaagacagccctgagcttccagaagtatcagatcgacgagctgggcaag
gagatcagaccttgtaggctgaagaagcgcccacccgtgcgggaggataagcggcccgcagcaaccaagaaggcaggacaggcc
aagaagaagaagtacccctatgacgtgcctgactacgccgggtatccctacgacgtgcctgattacgccgggtcctatccctac
gacgtgccagattacgctgcagctccagcagcgaagaaaaagaagctggattaagatctttttccctctgccaaaaattatggg
gacatcatgaagccccttgagcatctgacttctggctaataaaggaaatttattttcattgcaatagtgtgttggaattttttg
tgtctctca
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